ArticleAmerican journal of cancer research2013
Leptomeningeal metastases in breast cancer.
Article in American journal of cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- DEGRO guideline for personalized radiotherapy of brain metastases and leptomeningeal carcinomatosis in patients with breast cancer.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Guideline
- Article
- Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study.Breast cancer research and treatment · 2024Article
- The path to leptomeningeal metastasis.Nature reviews. Cancer · 2024Review
- Adeno-associated virus-mediated trastuzumab delivery to the central nervous system for human epidermal growth factor receptor 2+ brain metastasis.Cancer gene therapy · 2024Article
- The anatomic basis of leptomeningeal metastasis.The Journal of experimental medicine · 2024Review
- Local and systemic therapy in breast cancer patients with central nervous system metastases.Breast cancer research and treatment · 2022Article
- Determination of the Estrogen Receptor Status of Leptomeningeal Metastasis in Patients with Metastatic Breast Cancer Using [Nuclear medicine and molecular imaging · 2022Article
- A Novel Brain-Permeant Chemotherapeutic Agent for the Treatment of Brain Metastasis in Triple-Negative Breast Cancer.Molecular cancer therapeutics · 2021Article
- Assessment of Leptomeningeal Carcinomatosis Diagnosis, Management and Outcomes in Patients with Solid Tumors Over a Decade of Experience.European journal of breast health · 2021Article
- Autocrine GMCSF Signaling Contributes to Growth of HER2Cancer research · 2021Article
- Inhibition of Jumonji Histone Demethylases Selectively Suppresses HER2Cancer research · 2021Article
- Development of next-generation tumor-homing induced neural stem cells to enhance treatment of metastatic cancers.Science advances · 2021Article
- Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers.Science advances · 2021Article
- Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease.Frontiers in cellular neuroscience · 2021Review
- Corrigendum: Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease.Frontiers in cellular neuroscience · 2021Article
- Leptomeningeal carcinomatosis and breast cancer: a systematic review of current evidence on diagnosis, treatment and prognosis.Drugs in context · 2021Review
- Health care resource utilization and treatment of leptomeningeal carcinomatosis in the United States.Neuro-oncology practice · 2020Article
- Metastatic breast cancer cells induce altered microglial morphology and electrical excitability in vivo.Journal of neuroinflammation · 2020Article
- Metastatic brain tumors respond favorably to pyrotinib in a HER2-positive breast cancer following failure using trastuzumab.American journal of translational research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Central nervous system (CNS) metastasis from breast cancer may be characterized as either parenchymal brain metastasis (BM) or leptomeningeal (LM) metastasis. BM are much more common (about 80% of all CNS metastases), and have been more extensively studied than LM. CNS metastasis in breast cancer has been associated with reduced overall survival, with the shortest survival generally observed in cases of LM. Here, we review the epidemiology, prognostic factors, diagnostic tools, currently available treatments, and potential future therapies for LM from breast cancer.
Indexed as
Identifiers
23593536PMC3623833W1528402523What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.